Compare XPOF & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | CCCC |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 240.3M |
| IPO Year | 2021 | 2020 |
| Metric | XPOF | CCCC |
|---|---|---|
| Price | $7.86 | $2.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $11.69 | $8.50 |
| AVG Volume (30 Days) | 679.8K | ★ 1.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,135,000.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.38 | $1.09 |
| 52 Week High | $18.87 | $4.70 |
| Indicator | XPOF | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 49.03 |
| Support Level | $6.73 | $2.50 |
| Resistance Level | $8.23 | $2.69 |
| Average True Range (ATR) | 0.39 | 0.18 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 87.60 | 23.86 |
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.